Hansoh Pharmaceutical Group
$34.14Change from previous close: −3.29%Absolute change: −$1.16
At a glance
- Revenue growth
- +22.57%
- 2025 vs 2024
- Net income growth
- +27.07%
- 2025 vs 2024
- Net margin
- 37.0%
- 2024: 35.7%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2,337 | 3,133 | 3,605 | 1,180 | 2,682 | 1,970 | 1,146 | 967 | 1,774 | 1,493 |
| Depreciation and amortization | 197 | 194 | 197 | 185 | 217 | 182 | 185 | 186 | 158 | 146 |
| Capital expenditure | -251 | -183 | -173 | -120 | -102 | -127 | -92.6 | -86.9 | -186 | -208 |
| Investing cash flow | -5,048 | -5,649 | -1,506 | -3,761 | 2,369 | 32.1 | 1,042 | -467 | -5,468 | -2,680 |
| Financing cash flow | 4,103 | 1,534 | 20.0 | -1,870 | -4,196 | -703 | -50.5 | -763 | -54.8 | -379 |
| Dividends paid | — | -2,012 | — | -1,858 | — | -652 | — | -712 | — | -317 |
| Share repurchases | -12.7 | — | — | — | -33.7 | -35.4 | -79.5 | -18.6 | -58.1 | -58.0 |
| Debt issued | 4,137 | — | — | — | 500 | 900 | — | — | — | 24.2 |
| Debt repaid | -49.1 | -11.3 | -11.1 | -11.3 | -4,693 | -910 | -9.0 | -35.0 | -7.5 | -4.3 |
| Effect of exchange rates | -145 | -46.3 | -5.2 | -23.2 | -39.2 | -50.0 | -72.4 | 221 | -262 | -368 |
| Net change in cash | 1,248 | -1,029 | 2,115 | -4,474 | 816 | 1,249 | 2,065 | -41.4 | -4,011 | -1,934 |
| Free cash flow | 2,087 | 2,950 | 3,432 | 1,060 | 2,581 | 1,843 | 1,054 | 880 | 1,588 | 1,285 |
| Levered free cash flow | 2,105 | 1,913 | 3,249 | 39.8 | 2,361 | 1,047 | 1,022 | 28.8 | 1,424 | 598 |